HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 2,271: | Line 2,271: | ||
|- | |- | ||
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | |Anaplastic Large Cell Lymphoma, ALK-Positive | ||
| | |Miguel Gonzalez Mancera, MD | ||
| | |||
| | Sumire Kitahara, MD | ||
Cedars-Sinai, Los Angeles, CA | |||
|Complete | |||
|09/23/2022 | |||
| | | | ||
|- | |- | ||
|ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | |ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
|Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | ||
| | |Complete | ||
| | |09/23/2022 | ||
| | | | ||
|- | |- | ||
|Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | |Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | ||
| | |Breast Implant-Associated Anaplastic Large Cell Lymphoma | ||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | ||
| | |Pending | ||
| | | | ||
| | | | ||
|- | |- | ||
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| || || | | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||Issue - Rachel Burnside was working on this. Note says: "has prior content and name will change in 5th edition - Rachel working on this outside of production site to be replaced later by Nodal TFH Cell Lymphoma, Angioimmunoblastic-Type)". Where is her content as previous author names on 5th edition page||7/28/2023 | ||
| | | ||Pending|| ||SK|| || | ||
| | |Angioimmunoblastic T-cell Lymphoma | ||
| | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | ||
|Pending | |||
| | | | ||
| | | | ||
|- | |- | ||
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || | | |Nodal TFH cell lymphoma, follicular-type||Disease||Rachel Burnside||7/28/2023 | ||
| | | ||Pending|| ||SK|| || | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
| | |NEW (No Prior) | ||
|NEW (No Prior) | |||
|- | |- | ||
|Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| || | |Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| || | ||